Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Theolytics Ltd.

Theolytics is focused on developing category changing cancer therapies in the form of oncolytic viruses. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, backed by Oxford Science Innovation (OSI) and international life sciences investors Epidarex Capital, Taiho Ventures, and M Ventures. *

 

Period Start 2017-12-01 established (s-off)
  Predecessor University of Oxford
Products Industry BIOTECH
  Industry 2 oncolytic virus technology
Person Person Casebourne, Charlotte (Theolytics 202107 CEO + Co-Founder)
     
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street Roosevelt Drive
Innovation Building
  City OX3 7FZ Oxford, Oxfordshire
    Address record changed: 2024-01-05
     
Basic data Employees B: 11 to 50 (2021-06-26)
     
    * Document for »About Section«: Theolytics Ltd.. (7/8/21). "Press Release: Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor". Oxford.
     
   
Record changed: 2024-01-20

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Theolytics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top